Piper Jaffray Companies started coverage on shares of Motus GI (NASDAQ:MOTS) in a research report report published on Sunday. The brokerage issued an overweight rating and a $7.00 price target on the stock.
Shares of Motus GI (NASDAQ MOTS) opened at $4.79 on Friday. The firm has a market cap of $73.19 and a price-to-earnings ratio of -6.39. Motus GI has a twelve month low of $3.75 and a twelve month high of $5.30.
In other news, Chairman David P. Hochman acquired 115,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The shares were acquired at an average price of $5.00 per share, with a total value of $575,000.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive acquired 1,000,000 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was purchased at an average cost of $5.00 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 1,175,000 shares of company stock worth $5,875,000.
Motus GI Company Profile
Motus GI Holdings, Inc is a medical technology company. The Company is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The Pure-Vu system uses a precise mixture of water and air to loosen debris from the colon mucosa while simultaneously evacuating the bowel contents, clearing the way for the endoscopist to perform a high quality examination, even when the patient is not fully clean prior to their procedure.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.